TriLink BioTechnologies, a Maravai LifeSciences company, has launched its first mRNA synthesis kit featuring CleanCap® capping technology. This all-in-one kit integrates several innovative products to streamline mRNA synthesis for researchers.
The new in vitro transcription (IVT) kit is designed to deliver up to 2X more mRNA yield and up to 85% lower double-stranded RNA (dsRNA) compared to other kits on the market. It includes CleanCap AG (3′ OMe), a modified version of the original CleanCap AG, which boasts over 95% capping efficiency to improve protein expression.
To commemorate the launch and foster future innovation, TriLink is donating the first new kits to seven academic institutions across the U.S. and Europe. This initiative provides up to a combined 250mg of capped mRNAs, aiming to empower groundbreaking research in mRNA-based medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.